<DOC>
	<DOCNO>NCT01251484</DOCNO>
	<brief_summary>VEGF inhibition BEV may induce change tumor invasiveness treatment failure often associate remote metastasis . BEV may stop growth tumor cell block blood flow tumor . Cediranib , pan-VEGF inhibitor show promising result recurrent GBM . VEGF-blocking small molecule may overcome mechanism resistance , response BIBF-1120 circumstance may open new treatment option GBM . In additional , recurrent glioblastoma extremely poor prognosis , innovative therapy need .</brief_summary>
	<brief_title>BIBF 1120 Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion Written inform consent Histological verification primary GBM failure radiotherapy TMZ Previously receive radiotherapy TMZ More 4 week since follow prior treatment Chemotherapy ( 6 week nitrosureas mitomycin C ) Radiotherapy nontarget lesion lesion biopsied Investigational agent More 6 month since prior major surgery open biopsy recover ( 6 week require operation recurrent BGM ) ● ECOG performance status 01 Age &gt; 18 year Creatinine normal OR creatinine clearance ≥ 60 mL/min Fertile female must use anticonception ( p pill , IUD , depot injection gestagen , subdermal implantation , hormonal vaginal ring transdermal depot plaster , throughout study 3 month discontinuation study drug . Fertile men must use dobbelt barrier method ( preservative sperm inhibit creme ) female partner us mention contraception . Fertile male must use preservative . Exclusions criteria Prior treatment BIBF 1120 VEGFR inhibitor , except bevacizumab Group 2 Chemo , hormono , radio ( except brain extremity ) immunotherapy therapy monoclonal antibody small tyrosine kinase inhibitor within past 4 week prior treatment trial drug . Persistence clinically relevant therapy relate toxicity previous chemo and/or radiotherapy Treatment investigational drug treatment another clinical trial within past 4 week start therapy concomitantly trial Therapeutic anticoagulation ( except lowdose heparin and/or heparin flush need maintenance indwell intravenous devise ) antiplatelet therapy ( except lowdose therapy acetylsalicylic acid &lt; 325mg per day Major injury within past 10 day prior start study treatment incomplete wound heal and/or plan surgery ontreatment study period History clinically significant haemorrhagic thromboembolic event past 6 month Known inherited predisposition bleed thrombosis Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history infarction within past 12 month prior start study treatment , congestive heart failure &gt; NYHA II , serious cardiac arrhythmia , pericardial effusion ) Proteinuria CTCAE grade 2 great Hepatic function : total bilirubin outside normal limit ; ALT AST &gt; 1.5 ULN Coagulation parameter : International normalise ratio ( INR ) &gt; 2 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 50 % deviation institutional ULN Absolute neutrophil count ( ANC ) &lt; 1500/ml , platelet &lt; 100000/ml , Haemoglobin &lt; 9.0 g/dl Other malignancy within past 5 year basal cell skin cancer carcinoma situ cervix Active serious infection particular require systemic antibiotic antimicrobial therapy Active chronic hepatitis C and/or B infection Gastrointestinal disorder abnormality would interfere absorption study drug Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . Pregnancy breast feed Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>